



EXPRESS MAIL NO. EV335394213US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wen-Yang Wu et al.  
Application No. : 10/018,963  
Filed : May 21, 2002  
For : ANTIVIRAL AGENTS

Examiner : Lawrence E. Crane  
Art Unit : 1623  
Docket No. : 150070.401UCPC  
Date : September 13, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.


09/16/2004 FFANAI2 00000019 10018963

02 FC:1806  
03 FC:2201  
04 FC:2202

180.00 OP  
301.00 OP  
54.00 OP

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Carol R. Roth  
Registration No. 32,783

CR:ljt

Enclosures:

Form PTO-1449  
Cited References (5)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

\507462

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
150070.401USPCAPPLICATION NO.  
10/018,963**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Wen-Yang Wu et al.

FILING DATE

May 21, 2002

GROUP ART UNIT

1623

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AG					
	AH					
	AI					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Andries, K., "Discovery of pirodavir, a broad-spectrum inhibitor of rhinoviruses," in <i>The search for antiviral drugs</i> . Adams, J. and Merluzzi, VJ., (eds) Berkhauser, Boston USA, 1993, pgs. 179-209.
	AK	Arruda, E and Hayden, FG., "Clinical studies of antiviral agents for picornaviral infections," in <i>Antiviral Chemotherapy</i> , Jeffries, DJ. and DeClercq, E. (ed). John Wiley & Sons Ltd., Sussex, England, 1995, pgs. 321-355.
	AL	Rogers, JM et al., "Pleconaril. A broad spectrum antipicornavirus agent," in <i>Antiviral Chemotherapy 5</i> , Mills et al. (ed), Kluwer Academic/Plenum Publishers, NY, USA, 1999, pgs. 69-76.
	AM	Rotbart, HA et al., "Treatment of human enterovirus infections," <i>Antiviral Research</i> 38: 1-14, 1998.
	AN	Schiff, GM and Sherwood, JR, "Clinical activity of Pleconaril in an experimentally induced Cocksackievirus A21 respiratory infection," <i>The Journal of Infectious Diseases</i> , 181: 20-26, January 2000.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Date mailed: September 13, 2004